Diagnostic Center | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
Yesafili, received marketing authorization approval from the European Commission for the European Union
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Total transaction value of the divestment is Rs. 3,660 million
PhytoSquene now available for clinical and commercial use
Lack of technology transfer stands out as a formidable barrier
The agreement demonstrates a shared commitment to advance precision medicine and improve patient outcomes in the region
Subscribe To Our Newsletter & Stay Updated
